fenofibrate has been researched along with lovastatin in 43 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.65) | 18.7374 |
| 1990's | 26 (60.47) | 18.2507 |
| 2000's | 3 (6.98) | 29.6817 |
| 2010's | 10 (23.26) | 24.3611 |
| 2020's | 2 (4.65) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Hao, L; Hao, S; Sun, H; Wang, Z; Yu, P; Zhang, M; Zhang, X | 1 |
| Bard, JM; Bruckert, E; Camare, R; Dachet, C; Douste-Blazy, P; Drouin, P; Jacotot, B; Luc, G; Parra, HJ; Ziegler, O | 2 |
| Schlienger, JL | 1 |
| Agheli, N; Jacotot, B | 1 |
| Drouin, P; Ziegler, O | 1 |
| Dachet, C; De Gennes, JL; Douste-Blazy, P; Drouin, P; Fricker, J; Keller, U | 1 |
| Keller, U; Riesen, WF; Stohler, R | 1 |
| Brown, WV | 1 |
| Duncan, A; Murphy, MJ; O'Reilly, DS; Packard, CJ; Vallance, BD | 1 |
| Banks, D; Feher, MD; Foxton, J; Lant, AF; Wray, R | 1 |
| Hockwin, O; Paulus, U; Schmidt, J; Schmitt, C; von Bergmann, K | 1 |
| Ben Khalifa, F; Ftouhi, B; Kaabachi, A; Mebazaa, R; Mekaouer, A; Turki, S | 1 |
| Amouyel, P; Brousseau, T; Devulder, B; Fruchart, JC; Lecerf, JM; Luc, G | 1 |
| Shepherd, J | 1 |
| Devuyst, O; Goffin, E; Pirson, Y; van Ypersele de Strihou, C | 1 |
| Bonnefous, F; Debbas, N; Farnier, M; Irvine, A | 1 |
| Branchi, A; Fasoli, A; Gugliandolo, AG; Rovellini, A; Sommariva, D | 1 |
| Bélichard, P; Pruneau, D; Zhiri, A | 1 |
| Baigts, F; Bruckert, E; De Gennes, JL; Malbecq, W | 1 |
| Auwerx, J; Fruchart, JC; Staels, B; Van Tol, A | 1 |
| Boissonnat, P; de Lorgeril, M; Dureau, G; Monjaud, I; Salen, P | 1 |
| Hehnke, U; Kaffarnik, H; Schwartz, T; Steinmetz, A | 1 |
| Bambauer, R; Müller, UA; Schiel, R | 1 |
| Autier, P; Muls, E; Van Gaal, L; Vansant, G | 1 |
| Durrington, P | 1 |
| Sinzinger, H | 1 |
| Gholami, K; Maleki, M; Shafiee, A; Tavakoli, N | 1 |
| Kirchgässler, KU; Schiffner-Rohe, J; Stahlheber, U | 1 |
| Gan, W; Lin, R; Liu, J; Yang, G | 1 |
| Dimitri, E; Landry, P; Légaré, N; Tessier, S | 1 |
| Chang, CT; Hsu, WM; Huang, CC; Kuo, HL; Liang, CC; Lin, HH; Liu, YL; Wang, IK; Yeh, HC | 1 |
| Ajima, H; Akashi, S; Ezaki, O; Fujimaki, J; Kai, Y; Kamei, Y; Miura, S; Morita, A | 1 |
5 review(s) available for fenofibrate and lovastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Review of clinical studies of fenofibrate in combination with currently approved lipid-lowering drugs.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Colestipol; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipidemias; Lovastatin; Nicotinic Acids; Propionates; Simvastatin | 1989 |
The fibrates in clinical practice: focus on micronised fenofibrate.
Topics: Adolescent; Adult; Aged; Cholesterol, LDL; Coronary Disease; Drug Compounding; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin | 1994 |
Statins and fibrates in the management of diabetic dyslipidemia.
Topics: Diabetes Complications; Diabetes Mellitus; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Simvastatin | 1997 |
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis | 1998 |
14 trial(s) available for fenofibrate and lovastatin
| Article | Year |
|---|---|
A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Female; Fenofibrate; Humans; Hypercholesterolemia; In Vitro Techniques; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1992 |
Lipoprotein particle analysis comparing simvastatin and fenofibrate.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins; Apolipoproteins B; Double-Blind Method; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Lovastatin; Middle Aged; Simvastatin | 1991 |
Effect of simvastatin and fenofibrate on the fatty acid composition of hypercholesterolaemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol Esters; Double-Blind Method; Fatty Acids; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Lovastatin; Male; Middle Aged; Phospholipids; Simvastatin; Triglycerides | 1991 |
Safety, tolerability, and efficacy of simvastatin and fenofibrate--a multicenter study. Simvastatin-Fenofibrate Study Group.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Double-Blind Method; Female; Fenofibrate; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1990 |
[The efficacy and tolerance of simvastatin and fenofibrate in primary hypercholesterolemia].
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Tolerance; Female; Fenofibrate; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Placebos; Simvastatin | 1990 |
Effects of simvastatin and fenofibrate on serum lipoproteins and apolipoproteins in primary hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Cholesterol, HDL; Female; Fenofibrate; Humans; Hypercholesterolemia; Lipoproteins; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Propionates; Simvastatin; Triglycerides | 1989 |
Review of clinical studies of fenofibrate in combination with currently approved lipid-lowering drugs.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Colestipol; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipidemias; Lovastatin; Nicotinic Acids; Propionates; Simvastatin | 1989 |
[Therapeutic trial of simvastatin versus fenofibrate in primary hypercholesterolemia].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1994 |
Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Female; Fenofibrate; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lovastatin; Male; Middle Aged; Prognosis; Simvastatin; Triglycerides | 1994 |
Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Volatile; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1995 |
Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1996 |
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Longitudinal Studies; Lovastatin; Male; Middle Aged; Niacin; Pravastatin; Quality of Life | 1995 |
Comparison of the efficacy and safety of fenofibrate and lovastatin in patients with primary type IIa or IIb hyperlipidaemia.
Topics: Adult; Aged; Cholesterol; Female; Fenofibrate; Humans; Hyperlipidemias; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Time Factors; Triglycerides | 1998 |
Cost effectiveness of micronised fenofibrate and simvastatin in the short-term treatment of type IIa and type IIb hyperlipidaemia.
Topics: Anticholesteremic Agents; Double-Blind Method; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Retrospective Studies; Simvastatin | 1997 |
25 other study(ies) available for fenofibrate and lovastatin
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
Topics: 3T3-L1 Cells; AMP-Activated Protein Kinases; Animals; Chalcones; Chemistry Techniques, Synthetic; Hep G2 Cells; Humans; Metabolic Syndrome; Mice; Non-alcoholic Fatty Liver Disease; Signal Transduction; Stereoisomerism | 2020 |
[Evaluation of the addition of fenofibrate to the simvastatin-cholestyramine combination].
Topics: Anticholesteremic Agents; Cholestyramine Resin; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Lovastatin; Simvastatin | 1991 |
Iatrogenic profound hypoalphalipoproteinaemia: an unrecognised cause of very low HDL cholesterol.
Topics: Adult; Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Drug Interactions; Female; Fenofibrate; Humans; Hypolipoproteinemias; Lovastatin; Male; Middle Aged; Probucol; Simvastatin | 1995 |
Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.
Topics: Adult; Aged; Aspartate Aminotransferases; Bezafibrate; Cohort Studies; Coronary Disease; Creatine Kinase; Drug Therapy, Combination; Female; Fenofibrate; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Retrospective Studies; Simvastatin | 1995 |
Ocular drug safety and HMG-CoA-reductase inhibitors.
Topics: Color Perception; Contrast Sensitivity; Eye; Female; Fenofibrate; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intraocular Pressure; Lens, Crystalline; Lovastatin; Male; Middle Aged; Photography; Refraction, Ocular; Safety; Simvastatin; Visual Acuity | 1994 |
[Detection of the Arg 3500-->Gln mutation of B apolipoprotein. Value in clinical practice].
Topics: Adult; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Contraceptives, Oral, Combined; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Polymerase Chain Reaction; Simvastatin | 1995 |
Hypercholesterolemia treatment in a renal transplant patient.
Topics: Anticholesteremic Agents; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Humans; Hypercholesterolemia; Kidney Transplantation; Lovastatin; Male; Middle Aged; Postoperative Complications; Simvastatin | 1994 |
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol, Dietary; Combined Modality Therapy; Female; Fenofibrate; Fibrinogen; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1993 |
Effect of a long-term treatment with lovastatin or fenofibrate on hepatic and cardiac ubiquinone levels in cardiomyopathic hamster.
Topics: Animals; Body Weight; Cardiomyopathies; Cricetinae; Female; Fenofibrate; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Male; Mesocricetus; Myocardium; Ubiquinone | 1993 |
Effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in the rat.
Topics: Actins; Animals; Apolipoproteins; Cholestyramine Resin; Clofibrate; Fenofibrate; Gene Expression Regulation; Hypolipidemic Agents; Intestinal Mucosa; Lipid Metabolism; Lipoproteins, HDL; Liver; Lovastatin; Male; Niacin; Probucol; Rats; Rats, Wistar; Simvastatin | 1996 |
Fenofibrate, probucol, and other lipid-lowering treatments in heart transplant recipients.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Cyclosporine; Drug Interactions; Fenofibrate; Gemfibrozil; Heart Transplantation; Humans; Hypolipidemic Agents; Immunosuppressive Agents; Lovastatin; Probucol; Simvastatin | 1996 |
Effects of initial BMI and on-treatment weight change on the lipid-lowering efficacy of fibrates.
Topics: Body Mass Index; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Prospective Studies; Sex Factors; Simvastatin; Weight Loss | 1997 |
C-reactive protein-induced expression of CD40-CD40L and the effect of lovastatin and fenofibrate on it in human vascular endothelial cells.
Topics: C-Reactive Protein; CD40 Antigens; CD40 Ligand; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium, Vascular; Fenofibrate; Humans; Hypolipidemic Agents; Lovastatin; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Umbilical Cord | 2004 |
Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study.
Topics: Adult; Antipsychotic Agents; Atorvastatin; Cholesterol; Clozapine; Female; Fenofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Psychotic Disorders; Pyrroles; Retrospective Studies; Schizophrenia; Treatment Outcome; Triglycerides | 2008 |
Long-term use of fenofibrate is associated with increased prevalence of gallstone disease among patients undergoing maintenance hemodialysis.
Topics: Aged; Cross-Sectional Studies; Female; Fenofibrate; Gallstones; Humans; Hypolipidemic Agents; Kidney Failure, Chronic; Lovastatin; Male; Middle Aged; Prevalence; Renal Dialysis; Taiwan | 2011 |
Effects of fenofibrate and its combination with lovastatin on the expression of genes involved in skeletal muscle atrophy, including FoxO1 and its targets.
Topics: Animals; Atrophy; Drug Therapy, Combination; Fenofibrate; Forkhead Box Protein O1; Gene Expression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Mice, Inbred C57BL; Muscle, Skeletal; Muscular Atrophy; Rhabdomyolysis | 2021 |